Histopathological changes in rabbit uterus carcinoma after transcatheter arterial embolization using cisplatin.
The effects of chemoembolization with cisplatin on gynecological malignancy were investigated using rabbit uterine tumors. A group of 20 rabbits were subjected to inoculation of the uterus with 5 x 10(7) VX2 carcinoma cells and 4 weeks later were divided into four groups, each consisting of five rabbits: an untreated control group, a group given cisplatin intraarterially (IA), a group subjected to transcatheter arterial embolization (TAE) with Gelfoam particles and a group subjected to transcatheter chemoembolization (TACE) with Gelfoam particles plus 1 mg/kg cisplatin. All groups were examined histologically 2 days after treatment. The untreated control group was further investigated 4 weeks after inoculation. In the untreated control group, the tumor cell nuclei varied in size and were irregular in form, and multiple nuclei and nuclear division were also observed. No necrotic zones were found up to 4 weeks after inoculation. The IA group showed no necrosis, but a few apoptotic cells were scattered throughout the tumor. In the TACE group, necrosis was observed in the center of the tumors, but proliferating cells persisted at the periphery. In the TACE group, necrosis was observed in the central part with many apoptotic cells surrounding the necrotic region in layers. The proliferating cell nuclear antigen (PCNA) index was 95.88% in the untreated control group, 86.6% in the IA group, and 8.62% in the TACE group, indicating a significant reduction in cell proliferation in the TACE group. These findings suggest that TACE results in more effective cytotoxicity than the other two treatments in uterine cancer tumor transplants.
Harima
Y
Y
Department of Radiology, Kansai Medical University, Osaka, Japan.
Harima
K
K
Hasegawa
T
T
Shikata
N
N
Tanaka
Y
Y
D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017209:Apoptosis; D001158:Arteries; D002467:Cell Nucleus / Q000473:pathology; D016461:Chemoembolization, Therapeutic; D002945:Cisplatin / Q000008:administration & dosage*; D004621:Embolization, Therapeutic; D005260:Female; D009336:Necrosis; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D011817:Rabbits; D014594:Uterine Neoplasms / Q000276:immunology / Q000473:pathology / Q000628:therapy*
D000970:Antineoplastic Agents; D018809:Proliferating Cell Nuclear Antigen; D002945:Cisplatin